Utrecht and Qingdao, Sep 4th, 2020 – Hubrecht Organoid Technology (HUB) and BGI-Qingdao announced today that they have signed a Memorandum of Understanding (MoU) to form a collaboration to establish a joint Next Generation Diagnostics (NGD) center to improve personalised care, better treatments and cure as well as faster development of new safe medicines in China. The signing ceremony was conducted online in the Netherlands and China.
With their complementary expertise and technology, HUB and BGI will further develop and implement HUB Organoid Technology as predictive diagnostic tests allowing for accurate patient specific prediction of treatment responses initially with focus on cancer.
Pursuant to the MoU, HUB and BGI will establish a HUB-BGI Diagnostic Center in China. Strategic objectives include further development of predictive diagnostics based on HUB’s proprietary Organoid Technology. The collaboration encompasses integration of some of their respective technologies in particular BGI’s Next Generation Sequencing technology (NGS) and HUB Organoid Technology, to develop and improve NGD as an important tool to advance health care services by supporting clinical decisions for cancer patients in China.
“We are delighted to have BGI, a world leader in genomics and personalised technologies, as our partner in China. Together, and in collaboration with other Chinese partners, we intend to develop the joint center as a leader in services of personalised diagnostics for clinical use as well as a center for research, technology and innovation,” said Dr. Robert Vries, CEO of HUB.
“It is our pleasure to establish a partnership with HUB, a cutting-edge biotech company that has invented and developed many organoid technologies based-on patient-derived adult stem cells. Together with HUB, we will apply and further develop the organoid technologies as a “disease-in-a-dish” to improve disease diagnosis and treatments in China. We expect that global health will benefit from this collaboration as well.” Said Dr. Junnian Liu, General Manager and Executive Director of BGI-Qingdao.
HUB is a Dutch company that exploits the pioneering work of Prof. Dr. Hans Clevers, Hubrecht Institute, who discovered the HUB Organoid Technology to grow ‘mini-organs’ – organoids – from patient-derived adult stem cells. HUB Organoids perform as “Patients in the Lab” and allow a better and more precise understanding of tumor heterogeneity and patient drug response. This technology is, inter alia, used to establish patient derived organoids representing diseases such as cancer and to test these to assess different treatments options. HUB provides preclinical and clinical HUB Organoid Technology services to academia, hospitals, and the pharma/biotech industry.
For more information, please contact Dr. Bahar Ramezanpour (firstname.lastname@example.org), Chief Business Development Officer
BGI is a company that develops and provides genomic research, development, innovation, and services globally. One of BGI’s platforms provides genetic profiling of patient samples to support treatment decisions by physicians and clinicians. BGI´s Next Generation Sequencing technology is widely used for this service.
For more information, please contact Dr. Junnian Liu (email@example.com), Executive Director